Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825062 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4321277 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL209863 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL18909105 | 0.81 | TACR2 (0.49) | TACR2THRBGBA1HSD17B10ALOX15 | |
| SCHEMBL19275201 | 0.81 | TACR2 (0.49) | TACR2THRBGBA1SMN1; SMN2HSD17B10 | |
| SCHEMBL4668202 | 0.80 | SMN1; SMN2 (0.47) | THRBSMN1; SMN2CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4475140 | 0.79 | CACNA2D1 (0.58) | GBA1SMN1; SMN2TSHRCACNA2D1CACNA1B | |
| SCHEMBL27571743 | 0.79 | CACNA2D1 (0.58) | SMN1; SMN2CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL22030492 | 0.78 | TACR2 (0.46) | TACR2THRBGBA1HSD17B10ALOX15 | |
| SCHEMBL24585267 | 0.77 | TACR2 (0.46) | TACR2THRBHSD17B10ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | claimed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | claimed |
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PKD2, QPCT, CCNT2 | TACR2 107/4885THRB 2452/4885GBA1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.